Advanced Medicine

Neal Baer, editor of a collection of essays on CRISPR, says we must not overlook the dark side of the technology.

Manufacturing bottlenecks remain a key hurdle in CAR-T therapy. Can automation and digital integration change that?

Why researchers are excited about the potential of extracellular vesicles from umbilical cord-derived stem cells.

A new study reports targeted CRISPR delivery in retinal and neurological disease models – without viral vectors.

Bluebird bio’s financial situation is a stark reminder of the challenges of developing advanced therapies for rare diseases.

How precision analytics is driving the future of pharmaceuticals, from small molecules to CRISPR gene editing.

How do you design, refine, and optimize novel GLP-1 drugs that could improve patient experiences? With a computer, of course.

From gene therapy to novel excipients to trends in leadership and more. Check out some of our most popular videos.

How the right partnerships are helping streamline CGT manufacturing through robotics and digital tools.

Being part of the cell and gene therapy field is an incredible privilege, according to Frank Mathias, CEO, Oxford Biomedica.